All News

Pharmacy Times spoke with Josh Benner, pharmacist and CEO/founder of RxAnte, about medication misuse and the future of pharmacy in 2021.

Digital health products and solutions expand ways to guide prevention and treatment.

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, which activates the innate immune system in the tumor microenvironment and anti-tumor activity.

Caroline Carney, MD, MSc, FAPM, CPHQ, CMO of Magellan Health, discusses how pharmacists and other medical professionals can boost their brain health and keep a positive mindset while working during the pandemic.

Although ART has helped improve the health of those with HIV, they are at a greater risk of developing complications related to chronic inflammation, such as cardiovascular disease.

The plot clinical trial included 40 men and is believed to be the first published study to use progesterone to treat male COVID-19 patients whose lung functions have been compromised by the virus.

Shoulder injuries are a real concern because some health care workers may be new to administering vaccines.

Farah Towfic, PharmD, MBA, director, CEO operations at US Pharmacopeia (USP), discusses USP’s release of an updated version of its COVID-19 Vaccine Handling Toolkit in response to feedback from independent pharmacies to mass vaccination clinics.

Fractures, especially subsequent ones, positively correlate with an increased mortality risk.

A new study published in The American Journal of Clinical Nutrition found that for colorectal cancer survivors, maintaining a stable body weight may hide a loss of muscle and the development of fatty deposits in their muscles, which resulted in a 40% higher risk of premature death.

Pharmacies can reach patients who are not receiving vaccines from a pharmacy but are willing to receive them.

With the breakthrough device designation granted in 2019, the Signatera MRD test now has 3 designations for use across several cancer types and indications.

Technology is essential, but not all solutions meet every goal or offer the same capabilities.

If IVIG is commenced within 2 weeks from the onset of Guillain-Barre syndrome it can hasten recovery as much as plasma exchange, study indicates.

Results from the phase 3 KEYNOTE-775/study 309 trial found that Keytruda plus Lenvima reduced risk of death by 38%, with a median overall survival of 18.3 months

The FDA has approved the submission of a supplemental new drug application (sNDA) that expands the use of bupivacaine liposome injectable suspension to include patients aged 6 years and older for single-dose infiltration as a postsurgical local analgesia.

More than ever, confidence in objective, science-based data about therapeutics, such as the COVID-19 vaccine and other health care services, is a shared imperative across the pharmaceutical industry, health care communities, and the American public.

This vaccine rollout has become even more crucial for the US health care system, as new mutations of the coronavirus continue to emerge.

New results show that non-Hispanic Black patients with COVID-19 and type 1 diabetes have an additional risk of diabetic ketoacidosis beyond the risk of having diabetes or being of minority status.

Results from a phase 3 trial investigating the programmed cell death protein 1 inhibitor cemiplimab monotherapy compared to chemotherapy showed an overall survival benefit among patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.

Electricity may slow the speed at which breast cancer cells spread through the body, and in some cases may stop them entirely, according to a new study published in Bioelectricity.

Use basic knowledge of medications to be the first line of defense in ensuring safety and maintaining pharmacy workflow.

Among surveyed American adults, more than half were diagnosable with probable depression at baseline, in addition to 65% who had anxiety and 51% at risk for post-traumatic stress disorder.

Exposure to fine particulate, carbon monoxide, and ozone over time was linked to increased methylation, leading to higher rates of heart disease and other conditions in adulthood.

When analyzing the odds of death or hospitalization due to COVID-19, the researchers found that use of cytotoxic chemotherapy did not predict increased risk for either.

The researchers analyzed body composition data from the National Health and Nutrition Examination Survey (1999-2004) and cardiovascular disease data from the National Health and Nutrition Examination Survey (1999-2014).

The company received Fast Track designation from the FDA for GEN-1, a DNA-mediated interleukin-12 (IL-12) immunotherapy.

Following a review of the latest interim data released by AstraZeneca on its US phase 3 clinical trial assessing the 2-dose AZD1222 COVID-19 vaccine, the Data and Safety Monitoring Board (DSMB) expressed concern at the inclusion of what may have been outdated data.